Investigational drug · Phase 3
Acasunlimab
Also called: GEN1046, DuoBody-PD-L1×4-1BB
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "Acasunlimab"
First trial start
2024
Nov 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Acasunlimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Acasunlimab" as an intervention, largest first.
GenmabIndustry
NCT03917381 · 429 participants · Start May 14, 2019 · Primary completion Apr 1, 2025
Drug: Acasunlimab; Acasunlimab in combination with docetaxel (in a single expansion cohort) and 2 more · For: Solid Tumors
Sites: Phoenix, Arizona; New Haven, Connecticut; Jacksonville, Florida · 57 sites in all
- Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)Pivotal-lookingActive, not recruiting
GenmabIndustry
NCT06635824 · 191 participants · Start Nov 25, 2024 · Primary completion Jul 30, 2027
Drug: Acasunlimab; Pembrolizumab and 1 more · For: PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Sites: Tucson, Arizona; Los Angeles, California; Vallejo, California · 247 sites in all
- Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerPivotal-lookingTerminated
GenmabIndustry
NCT05117242 · 125 participants · Start Oct 27, 2021 · Primary completion Dec 2, 2024
Drug: Acasunlimab; Pembrolizumab · For: Non Small Cell Lung Cancer Metastatic
Sites: Santa Rosa, California; Fort Myers, Florida; St. Petersburg, Florida · 40 sites in all
GenmabIndustry
NCT04937153 · 18 participants · Start Jun 15, 2021 · Primary completion Oct 1, 2024
Drug: Acasunlimab; Pembrolizumab · For: Solid Tumor
Sites: Chiba, Japan; Tokyo, Japan
GenmabIndustry
NCT06984328 · 1 participants · Start Jul 25, 2025 · Primary completion May 15, 2026
Drug: Acasunlimab; Pembrolizumab · For: Cutaneous Melanoma; Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID); Metastatic Cutaneous Melanoma (Stage IV)
Sites: Nashville, Tennessee; San Juan, Puerto Rico
- GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial CancerWithdrawn
GenmabIndustry
NCT06046274 · 0 participants · Start Oct 1, 2023 · Primary completion Apr 1, 2028
Drug: Pembrolizumab; Acasunlimab · For: Advanced Endometrial Cancer
Sites: Orlando, Florida; New Brunswick, New Jersey; Brussels, Belgium · 29 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors.
Yamamoto N, Bajaj G, Adams HC, et al. · Int J Clin Oncol 2026
- Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects.
Capello M, Sette A, Plantinga T, et al. · J Immunother Cancer 2025
- Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A, Garralda E, Altintas I, et al. · Cancer Discov 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.